Q301 - Thyro Seq v3 Genomic Classifier (GC) Testing

The Department of Veterans Affairs, Network Contracting Office (NCO) 10, intends to negotiate a sole source contract for molecular diagnostic testing services using the ThyroSeq v3 Genomic Classifier (GC). The contract will be awarded to CYTOPATH BIOPY LAB INC, as they are the sole source provider of this test in the United States. The VA Northeast Ohio Healthcare System (VANEOHS), Pathology and Laboratory Medicine Service (PALMS), requires this testing service. Key aspects of the opportunity include: • The ThyroSeq v3 Genomic Classifier is a proprietary molecular assay exclusively developed, validated, and performed by CBL PATH. • The Government believes that only the proposed candidate possesses the required capabilities to meet this requirement. • Responses to this notice of intent to sole source must demonstrate the ability to comply with the requirement and show that competition would be advantageous to the Government.